Literature DB >> 26666365

Prostate cancer: Cardiac mortality associated with ADT plus radiotherapy.

Michel Bolla1, Gilles Créhange2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26666365     DOI： 10.1038/nrurol.2015.295

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.

Authors:  Paul L Nguyen; Youjin Je; Fabio A B Schutz; Karen E Hoffman; Jim C Hu; Arti Parekh; Joshua A Beckman; Toni K Choueiri
Journal:  JAMA       Date:  2011-12-07       Impact factor: 56.272

2.  Long-term Follow-up of a Randomized Trial of Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.

Authors:  Anthony V D'Amico; Ming-Hui Chen; Andrew Renshaw; Marian Loffredo; Philip W Kantoff
Journal:  JAMA       Date:  2015 Sep 22-29       Impact factor: 56.272

3.  Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction.

Authors:  Paul L Nguyen; Ming-Hui Chen; Joshua A Beckman; Clair J Beard; Neil E Martin; Toni K Choueiri; Jim C Hu; Karen E Hoffman; Daniel E Dosoretz; Brian J Moran; Sharon A Salenius; Michelle H Braccioforte; Philip W Kantoff; Anthony V D'Amico; Ronald D Ennis
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-06-25       Impact factor: 7.038

4.  Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.

Authors:  Sean O'Farrell; Hans Garmo; Lars Holmberg; Jan Adolfsson; Pär Stattin; Mieke Van Hemelrijck
Journal:  J Clin Oncol       Date:  2015-03-02       Impact factor: 44.544

5.  External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

Authors:  Michel Bolla; Geertjan Van Tienhoven; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Ignace Billiet; José Lopez Torecilla; Raphael Pfeffer; Carmel Lino Cutajar; Theodore Van der Kwast; Laurence Collette
Journal:  Lancet Oncol       Date:  2010-10-07       Impact factor: 41.316

6.  Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.

Authors:  Glenn N Levine; Anthony V D'Amico; Peter Berger; Peter E Clark; Robert H Eckel; Nancy L Keating; Richard V Milani; Arthur I Sagalowsky; Matthew R Smith; Neil Zakai
Journal:  Circulation       Date:  2010-02-01       Impact factor: 29.690

7.  Duration of androgen suppression in the treatment of prostate cancer.

Authors:  Michel Bolla; Theodorus M de Reijke; Geertjan Van Tienhoven; Alphonsus C M Van den Bergh; Jorg Oddens; Philip M P Poortmans; Eliahu Gez; Paul Kil; Atif Akdas; Guy Soete; Oleg Kariakine; Elsbietha M van der Steen-Banasik; Elena Musat; Marianne Piérart; Murielle E Mauer; Laurence Collette
Journal:  N Engl J Med       Date:  2009-06-11       Impact factor: 91.245

8.  Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.

Authors:  Jason A Efstathiou; Kyounghwa Bae; William U Shipley; Gerald E Hanks; Miljenko V Pilepich; Howard M Sandler; Matthew R Smith
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

9.  Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.

Authors:  Anthony V D'Amico; Ming-Hui Chen; Andrew A Renshaw; Marian Loffredo; Philip W Kantoff
Journal:  JAMA       Date:  2008-01-23       Impact factor: 56.272

10.  Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.

Authors:  Jason A Efstathiou; Kyounghwa Bae; William U Shipley; Gerald E Hanks; Miljenko V Pilepich; Howard M Sandler; Matthew R Smith
Journal:  Eur Urol       Date:  2008-01-15       Impact factor: 20.096
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.